Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
31
05
2021
revised:
20
08
2021
accepted:
14
10
2021
pubmed:
21
10
2021
medline:
8
4
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
To investigate the prognostic relevance of temporal muscle thickness (TMT) as a surrogate parameter of skeletal muscle status in patients with newly diagnosed glioblastoma. We assessed TMT in cranial MRI of 755 patients enrolled in the CENTRIC EORTC 26071-22072 study ( Patients at risk of sarcopenia (CENTRIC; TMT identifies ambulatory patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention may prevent skeletal muscle loss and improve patient outcome.
Identifiants
pubmed: 34667022
pii: 1078-0432.CCR-21-1987
doi: 10.1158/1078-0432.CCR-21-1987
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-136Informations de copyright
©2021 American Association for Cancer Research.
Références
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:iv1–iv96.
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–113.
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adhulthood. Nat Rev Clin Oncol. 2021;18:170–86.
Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S, et al. The accuracy of predicting survival in individual patients with cancer. J Neurosurg. 2014;120:24–30.
Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer. 1999;7:332–5.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis—report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412–23.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.
Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumors of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.
Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2016;26:1359–67.
Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumors: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
Zakaria HM, Wilkinson BM, Pennington Z, Saadeh YS, Lau D, Chandra A, et al. Sarcopenia as a prognostic factor for 90-day and overall mortality in patients undergoing spine surgery for metastatic tumors: a multicenter retrospective cohort study. Neurosurgery. 2020;87:1025–36.
Hasegawa Y, Yoshida M, Sato A, Fujimoto Y, Minematsu T, Sugama J, et al. Temporal muscle thickness as a new indicator of nutritional status in older individuals. Geriatr Gerontol Int. 2019;19:135–40.
Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U, et al. High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases. PLoS One. 2018;13:e0207849.
Steindl A, Leitner J, Schwarz M, Nenning K-H, Asenbaum U, Mayer S, et al. Sarcopenia in neurological patients: standard values for temporal muscle thickness and muscle strength evaluation. Journl Clin Med. 2020;9:1272.
Hasegawa Y, Yoshida M, Sato A, Fujimoto Y, Minematsu T, Sugama J, et al. A change in temporal muscle thickness is correlated with past energy adequacy in bedridden older adults: a prospective cohort study. BMC Geriatr. 2021;21:182.
Nozoe M, Kubo H, Kanai M, Yamamoto M, Okakita M, Suzuki H, et al. Reliability and validity of measuring temporal muscle thickness as the evaluation of sarcopenia risk and the relationship with functional outcome in older patients with acute stroke. Clin Neurol Neurosurg. 2021;201:106444.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicenter, randomized, open-label, phase III trial. Lancet Oncol. 2014;15:1100–8.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. Two cilengitide regimes in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17:708–17.
Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, et al. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. Eur Radiol. 2017;27:3167–73.
Field A. Discovering Statistics using IBM SPSS Statistics, 4th edition. 2013;324–6.
Katsuki M, Yamamoto Y, Uchiyama T, Wada N, Kakizawa Y. Clinical characteristics of aneurysmal subarachnoid hemorrhage in the elderly over 75; would temporal muscle be a potential prognostic factor as an indicator of sarcopenia?. Clin Neurol Neurosurg. 2019;186:105535.
Furtner J, Berghoff AS, Schöpf V, Reumann R, Pascher B, Woitek R, et al. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. J Neurooncol. 2018;140:173–8.
Katsuki M, Suzuki Y, Kunitoki K, Sato Y, Sasaki K, Mashiyama S, et al. Temporal muscle as an indicator of sarcopenia is independently associated with Hunt and Kosnik grade on admission and the modified rankin scale score at 6 months of patients with subarachnoid hemorrhage treated by endovascular coiling. World Neurosurg. 2020;137:e526–34.
Katsuki M, Kakizawa Y, Nishikawa A, Yamamoto Y, Uchiyama T. Temporal muscle thickness and area are independent prognostic factors in patients aged 75 or younger with aneurysmal subarachnoid hemorrhage treated by clipping. Surg Neurol Int. 2021;12:151.
An G, Ahn S, Park J-S, Jeun S-S, Hong Y-K. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol. 2021;147:901–9.
Yesil CH, HC E. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?. Asia Pac J Clin Oncol. 2020;16:e223–7.
Furtner J, Genbrugge E, Gorlia T, Bendszus M, Nowosielski M, Golfinopoulos V, et al. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro Oncol. 2019;21:1587–94.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis, and management. J Nutr Health Aging. 2018;22:1148–61.
Storer TW, Basaria S, Traustadottir T, Harman SM, Pencina K, Li Z, et al. Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men. J Clin Endocinol Metab. 2017;102:583–93.
Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, et al. Myostation antibody (LY2495655) in older weak fallers: a proof-of-concept, randomized, phase II trial. Lancet Diabetes Endocinol. 2015;3:948–57.
Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diganosed glioblastoma multiforme. J Clin Oncol. 2015;33:4145–50.
Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trail. Lancet Oncol. 2012;13:916–26.
Chang EL, Yi W, Allen PK, Levin VA, Sawaya RE, Maor MH. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma pateints: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;56:519–28.
Silva AM, Shen W, Heo M, Gallagher D, Wang Z, Sardinha LB, et al. Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol. 2010;22:76–82.
Fukushima H, Koga F. Impact of sarcopenia in the management of urological cancer patients. Expert Rev Anticancer Ther. 2017;17:455–66.
Sandri M. Autophagy in skeletal muscle. FEBS Lett. 2010;584:1411–6.